1 Min Read
Nov 3 (Reuters) - Immunovaccine Inc
* Neoepitope peptides formulated in immunovaccine’s depovax(tm) vaccine platform show significant positive results in preclinical studies Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.